Toripalimab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Nasopharyngeal Carcinoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 3 · under NMPA reviewCholangiocarcinoma · Phase 3

Also approved (2)
US
  • First-line Treatment of Metastatic or Recurrent, Locally Advanced NPC with Cisplatin and Gemcitabine LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).
Product first approved 2023Outside this platform's coverageFDA label
EU
  • Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Product first approved 2024EMA

Company guidance: data expected 2H 2026 (NCT07796126; Coherus BioSciences, Inc., 5 Aug 2026). “● The Phase 1b dose-optimization studies evaluating tagmokitug in combination with toripalimab in second-line head and neck squamous cell carcinoma (HNSCC) and upper gastrointestinal adenocarcinomas remain ongoing, with initial data readouts expected in 2H 2026.” Source ↗

Company guidance: data expected 2H 2026 (Coherus BioSciences, Inc., 5 Aug 2026). “● The Phase 1b/2a study evaluating the tagmokitug and toripalimab combination in fourth-line and beyond colorectal cancer with no liver metastasis, is fully enrolled, with initial data expected in 2H 2026.” Source ↗

Company guidance: topline data expected 1H 2027 (Coherus BioSciences, Inc., 9 Nov 2026). “● Enrollment in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC is complete and the first data readout is expected in 1H 2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (56)
Cholangiocarcinoma
Nasopharyngeal Carcinoma
NCT07154069 · Sun Yat-sen University
2025-11-13 – 2033-09 · Nasopharyngeal Cancinoma (NPC)
What this study did
NCT04778956 · Sun Yat-sen University
2021-03-03 – 2033-03-03 · Nasopharyngeal Carcinoma, PD-1, Surgery
What this study did
NCT07540390 · Sun Yat-sen University
2026-05-08 – 2032-12-31 · Nasopharyngeal Carcinoma
What this study did
NCT06561763 · Sun Yat-sen University
2024-08-20 – 2031-08-20 · High Risk Locally Advanced Nasopharyngeal Carcinoma
What this study did
NCT06277050 · Jiangxi Provincial Cancer Hospital
2024-03-07 – 2031-02-20 · Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy
What this study did
NCT06712888 · Sun Yat-sen University
2025-02-17 – 2030-11-26 · Nasopharyngeal Carcinoma (NPC)
What this study did
NCT05340491 · Sun Yat-sen University
2022-04-01 – 2028-12 · Nasopharyngeal Carcinoma
What this study did
NCT06228079 · Eye & ENT Hospital of Fudan University
2024-06-25 – 2028-06-30 · Recurrent Nasopharyngeal Carcinoma
What this study did
NCT04376866 · Cancer Hospital of Guangxi Medical University
2020-06-28 – 2028-04 · Recurrent Nasopharyngeal Carcinoma
What this study did
NCT05869227 · XIANG YANQUN
2023-04-28 – 2027-12-20 · Nasopharyngeal Carcinoma, Maintenance Therapy
What this study did
NCT06026878 · Air Force Military Medical University, China
2023-09-01 – 2027-09-30 · Nasopharyngeal Carcinoma
What this study did
NCT04453813 · Sun Yat-sen University
2020-07-03 – 2027-07 · Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
What this study did
NCT06235203 · Eye & ENT Hospital of Fudan University
2024-07-09 – 2027-06-30 · Recurrent Nasopharyngeal Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07608159 · Shanghai Pulmonary Hospital, Shanghai, China
2026-05 – 2030-05 · Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy, Neoadjuvant Chemoimmunotherapy, Surgery
What this study did
NCT04772287 · Shanghai Pulmonary Hospital, Shanghai, China
2021-03-31 – 2027-12-30 · Non Small Cell Lung Cancer
What this study did
NCT06505837 · Shanghai Junshi Bioscience Co., Ltd.
2024-07-11 – 2026-12-30 · Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
What this study did
NCT03924050 · Shanghai Junshi Bioscience Co., Ltd.
2019-05-06 – 2025-02-24 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07629817 · Henan Cancer Hospital
2026-06-16 – 2032-03-15 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07332221 · Henan Cancer Hospital
2026-01-20 – 2031-10-01 · Esophageal Cancer
What this study did
NCT06647563 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2024-11-01 – 2030-09-30 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT07392060 · Shanghai Jiatan Pharmatech Co., Ltd
2026-02-28 – 2030-06-30 · Cervical Cancer Metastatic
What this study did
NCT07177794 · Sun Yat-sen University
2025-09-10 – 2030-05-31 · Esophageal Cancer, Chemoradiotherapy
What this study did
NCT06441344 · Taizhou Hospital
2024-07-01 – 2030-05-01 · SCLC, Maintenance Treatment
What this study did
NCT06977893 · First Affiliated Hospital of Zhejiang University
2025-03-24 – 2030-03-23 · HR+/HER2- Breast Cancer
What this study did
NCT07584135 · NingBo Junyan Hongshi Biosciences Co., Ltd
2026-05-28 – 2029-12-31 · Gastric Adenocarcinoma
What this study did
NCT07246330 · Tianjin Medical University Cancer Institute and Hospital
2026-03-23 – 2029-12-15 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT06095583 · Shanghai Junshi Bioscience Co., Ltd.
2023-11-15 – 2029-07-31 · Limited-stage Small Cell Lung Cancer (LS-SCLC)
What this study did
NCT06952621 · Tang-Du Hospital
2026-02-01 – 2028-12-28 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT06592326 · Mabwell (Shanghai) Bioscience Co., Ltd.
2024-08-22 – 2028-12 · Urothelial Carcinoma
What this study did
NCT07445295 · Chipscreen Biosciences, Ltd.
2026-03-31 – 2028-11-30 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT07362186 · LaNova Medicines Limited
2026-04-30 – 2028-09-28 · Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
What this study did
NCT05180734 · Shanghai Junshi Bioscience Co., Ltd.
2022-02-10 – 2028-07-31 · Gastric or Esophagogastric Junction Adenocarcinoma
What this study did
NCT05302284 · RemeGen Co., Ltd.
2022-06-14 – 2028-04-30 · Urothelial Carcinoma, HER2-expressing
What this study did
NCT05738694 · ZHOU FANGJIAN
2023-04-19 – 2027-12-31 · Renal Cell Carcinoma, Neoadjuvant
What this study did
NCT06170489 · Shanghai Junshi Bioscience Co., Ltd.
2023-12-28 – 2027-09-30 · Hodgkin Lymphoma
What this study did
NCT04848753 · Shanghai Junshi Bioscience Co., Ltd.
2021-05-12 – 2027-05-12 · Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
What this study did
NCT04523493 · Shanghai Junshi Bioscience Co., Ltd.
2020-06-29 – 2027-03-31 · Advanced Hepatocellular Carcinoma (HCC)
What this study did
NCT06201065 · Sun Yat-sen University
2023-12-26 – 2026-12-26 · Hepatocellular Carcinoma
What this study did
NCT07371897 · Sun Yat-sen University
2026-06-30 – 2026-09-30 · Head and Neck Squamous Cell Carcinoma HNSCC
What this study did
NCT05669092 · Zhejiang Cancer Hospital
2022-11-01 – 2025-12-31 · Toripalimab, Radiation
What this study did
NCT05015621 · Hutchison Medipharma Limited
2021-09-18 – 2025-05-31 · Advanced Neuroendocrine Carcinoma
What this study did
NCT04085276 · Shanghai Junshi Bioscience Co., Ltd.
2018-12-21 – 2025-02-28 · Triple-Negative Breast Cancer
What this study did
NCT04709380 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2021-03-02 – 2025-02-05 · Radiotherapy, Toripalimab, Sorafenib, Advanced Hepatocellular Carcinoma
What this study did
NCT04723004 · Shanghai Junshi Bioscience Co., Ltd.
2020-10-15 – 2024-05-31 · Advanced Hepatocellular Carcinoma (HCC)
What this study did
NCT04394975 · Shanghai Junshi Bioscience Co., Ltd.
2020-08-20 – 2024-04-02 · Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
What this study did
NCT05056337 · Shanghai Zhongshan Hospital
2021-08-01 – 2023-12-01 · Hepatocellular Carcinoma
What this study did
Phase 2/3 (12)
Cholangiocarcinoma
NCT04669496 · Shanghai Zhongshan Hospital
2021-01-20 – 2026-12 · Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy
What this study did
Nasopharyngeal Carcinoma
NCT04890522 · Sun Yat-sen University
2021-07-01 – 2028-12-31 · Nasopharyngeal Carcinoma, Metastasis, Chemotherapy, Immunotherapy, Survival
What this study did
Other / comorbidity
NCT07608224 · West China Hospital
2026-06-20 – 2030-12-31 · Urinary Bladder Neoplasms
What this study did
NCT07653451 · Peking University Cancer Hospital & Institute
2026-07-01 – 2028-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT07935759 · The First Hospital of Jilin University
2025-05-16 – 2028-12-31 · Rectal Cancer
What this study did
NCT03859128 · Shanghai Junshi Bioscience Co., Ltd.
2019-03-05 – 2027-12-31 · Hepatocellular Carcinoma
What this study did
NCT03691454 · Peking University
2018-06-28 – 2027-06-30 · Gastric Adenocarcinoma
What this study did
NCT05125055 · Shanghai Jiao Tong University School of Medicine
2021-10-01 – 2026-12-30 · Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy
What this study did
NCT05980481 · RemeGen Co., Ltd.
2023-08-04 – 2026-10-10 · Gastric Cancer
What this study did
NCT05817201 · Taizhou Hospital
2022-07-01 – 2024-12-31 · Esophageal Cancer, Radiation Therapy, Immunotherapy, Chemotherapy
What this study did
NCT03992911 · Peking University
2019-06-19 – 2023-06-20 · Neuroendocrine Carcinoma of the Bladder
What this study did
Phase 2 (342)
Cholangiocarcinoma
NCT07685535 · Shanghai Zhongshan Hospital
2026-06-30 – 2028-12-31 · Liver Cancer
What this study did
NCT06717464 · Tianjin Medical University Cancer Institute and Hospital
2024-11-12 – 2027-12-31 · Gallbladder Cancer, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma
What this study did
NCT06852287 · Tianjin Medical University Cancer Institute and Hospital
2024-09-01 – 2026-09-01 · Intrahepatic Cholangiocarcinoma (Icc), Gall Bladder Cancer
What this study did
NCT07304388 · Sun Yat-sen University
2023-02-10 – 2025-06-01 · Intrahepatic Cholangiocarcinoma (Icc)
What this study did
NCT05448183 · Xuhua Duan
2022-06-15 – 2024-05-15 · Extrahepatic Cholangiocarcinoma
What this study did
NCT04361331 · Shanghai Zhongshan Hospital
2020-03-06 – 2023-09-01 · Cholangiocarcinoma, Intrahepatic
What this study did
NCT04506281 · Shanghai Zhongshan Hospital
2020-08-10 – 2023-08 · Cholangiocarcinoma, Intrahepatic
What this study did
NCT04961788 · Shanghai Zhongshan Hospital
2021-07-01 – 2022-12-31 · Intrahepatic Cholangiocarcinoma
What this study did
NCT03982680 · Jiangmen Central Hospital
2019-07-13 – 2021-12-30 · Advanced Cholangiocarcinoma
What this study did
NCT03951597 · Shanghai Zhongshan Hospital
2019-05-10 – 2021-11-10 · Cholangiocarcinoma, Intrahepatic
What this study did
Nasopharyngeal Carcinoma
NCT07110558 · Sun Yat-sen University
2025-08-15 – 2032-08-14 · Nasopharyngeal Cancinoma (NPC)
What this study did
NCT07362979 · Sun Yat-sen University
2026-03-12 – 2031-03-12 · Nasopharyngeal Cancinoma (NPC)
What this study did
NCT07555860 · Sun Yat-sen University
2026-04-20 – 2029-12-31 · Nasopharyngeal Carcinoma
What this study did
NCT07136519 · Affiliated Hospital of Guangdong Medical University
2025-07-30 – 2029-12-31 · Nasopharyngeal Carcinoma (NPC)
What this study did
NCT05484375 · Affiliated Cancer Hospital & Institute of Guangzhou Medical University
2022-09 – 2029-09 · Metastatic Nasopharyngeal Carcinoma
What this study did
NCT06987123 · Sun Yat-sen University
2025-05-18 – 2029-06-01 · Nasopharyngeal Carcinoma (NPC)
What this study did
NCT06912711 · Sun Yat-sen University
2025-05-16 – 2029-04-20 · Nasopharyngeal Carcinoma
What this study did
NCT06605131 · Sun Yat-sen University
2025-04-17 – 2029-02-25 · Nasopharyngeal Cancinoma (NPC)
What this study did
NCT06592599 · Stanford University
2024-09-03 – 2029-01 · Nasopharyngeal Carcinoma
What this study did
NCT06323239 · Sun Yat-sen University
2024-07-15 – 2028-12 · Nasopharyngeal Carcinoma
What this study did
NCT07388836 · Fujian Cancer Hospital
2026-03-01 – 2028-05 · Locally Advanced Nasopharyngeal Carcinoma
What this study did
NCT05813626 · Zhejiang Cancer Hospital
2023-04-21 – 2027-10-30 · Nasopharyngeal Carcinoma
What this study did
NCT06851247 · Sun Yat-sen University
2025-01-03 – 2027-06 · Nasopharyngeal Carcinoma
What this study did
NCT04517214 · Fudan University
2020-11-01 – 2026-12-31 · Nasopharyngeal Carcinoma
What this study did
NCT07920250 · Affiliated Hospital of Guangdong Medical University
2024-11-01 – 2026-07-01 · Nasopharyngeal Carcinoma (NPC), Radiation-induced Oral Mucositis, Head and Neck Neoplasms
What this study did
NCT04447326 · First Affiliated Hospital of Guangxi Medical University
2020-06 – 2026-06 · Nasopharyngeal Carcinoma
What this study did
NCT05147844 · Xinqiao Hospital of Chongqing
2022-03-01 – 2026-03-01 · Nasopharyngeal Carcinoma
What this study did
NCT04446663 · First People's Hospital of Foshan
2020-07-15 – 2024-12-15 · Nasopharyngeal Neoplasms
What this study did
NCT04996758 · Sun Yat-sen University
2021-10-30 – 2024-12-01 · Nasopharyngeal Carcinoma, Recurrent or Metastatic Nasopharyngeal Carcinoma
What this study did
NCT04398056 · Sun Yat-sen University
2019-04-01 – 2024-07-01 · Nasopharyngeal Carcinoma
What this study did
NCT05229315 · XIANG YANQUN
2022-03-12 – 2023-12 · Nasopharyngeal Carcinoma, T2-3N0 or T1-2N1, EBV-DNA≤4000 Copy/ml
What this study did
NCT03925090 · Sun Yat-sen University
2019-12-08 – 2023-10 · Nasopharyngeal Carcinoma
What this study did
NCT04955886 · Fujian Cancer Hospital
2021-08 – 2023-08 · Nasopharyngeal Carcinoma
What this study did
NCT04421469 · Fujian Cancer Hospital
2020-06-15 – 2023-06-15 · Nasopharyngeal Carcinoma
What this study did
NCT04405622 · Sun Yat-sen University
2020-05-30 – 2023-05 · Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect, Immunotherapy
What this study did
NCT03854838 · Sun Yat-sen University
2019-05-01 – 2023-02-01 · Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
What this study did
NCT04992988 · Cancer Hospital of Guangxi Medical University
2020-06-28 – 2022-06 · Nasopharyngeal Carcinoma, Toripalimab, Recurrent Nasopharyngeal Squamous Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07855965 · West China Hospital
2026-09-10 – 2033-08-05 · Carcinoma, Non-Small-Cell Lung (NSCLC)
What this study did
NCT06221670 · Tianjin Medical University Cancer Institute and Hospital
2024-03-20 – 2031-03-20 · NSCLC
What this study did
NCT07039656 · Wen-zhao ZHONG
2025-01-01 – 2030-12-31 · Stage IB-IIIB NSCLC, Stage IIB-III NSCLC
What this study did
NCT05891080 · Shanghai Pulmonary Hospital, Shanghai, China
2023-07-01 – 2030-07-01 · Stage III Non-small Cell Lung Cancer
What this study did
NCT06269211 · Ruijin Hospital
2024-04-20 – 2030-01-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT06706219 · Hunan Province Tumor Hospital
2026-05-10 – 2029-12-31 · Non Small Cell Lung Cancer (Stage III)
What this study did
NCT06426511 · Sun Yat-sen University
2024-12-01 – 2029-12-01 · Lung Cancer, Nonsmall Cell
What this study did
NCT07493980 · Shanghai Pulmonary Hospital, Shanghai, China
2026-03 – 2029-01-01 · NSCLC Stage II
What this study did
NCT07358689 · Tianjin Medical University Cancer Institute and Hospital
2026-06-30 – 2029-01-01 · NSCLC
What this study did
NCT07819578 · Shaodong Hong
2026-10-01 – 2028-12-01 · Non-Small Cell Lung Cancer
What this study did
NCT06127303 · Shanghai Chest Hospital
2024-04-02 – 2028-04-02 · Non-small Cell Lung Cancer
What this study did
NCT07438600 · Tianjin Medical University Cancer Institute and Hospital
2026-02-24 – 2028-02-28 · NSCLC (Non-small Cell Lung Cancer)
What this study did
Phase 1/2 (70)
Nasopharyngeal Carcinoma
NCT07258979 · MediLink Therapeutics (Suzhou) Co., Ltd.
2025-11-05 – 2028-05 · Recurrent or Metastatic Nasopharyngeal Carcinoma
What this study did
NCT07320963 · Sun Yat-sen University
2026-03-31 – 2028-03-28 · Nasopharyngeal Carcinoma
What this study did
NCT05341193 · Sun Yat-sen University
2022-04-30 – 2025-12-30 · Nasopharyngeal Carcinoma
What this study did
NCT04929080 · Shanghai Junshi Bioscience Co., Ltd.
2021-05-11 – 2023-03-06 · Head and Neck Squamous Cell Carcinom, Nasopharyngeal Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07169994 · MediLink Therapeutics (Suzhou) Co., Ltd.
2025-09-02 – 2027-11-30 · Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer
What this study did
NCT05821933 · RemeGen Co., Ltd.
2023-09-07 – 2026-09-01 · NSCLC
What this study did
NCT05955105 · Innolake Biopharm
2023-07-25 – 2026-07-24 · Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Melanoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Classic Hodgkin Lymphoma
What this study did
NCT04797702 · Shanghai Junshi Bioscience Co., Ltd.
2021-04-21 – 2022-11-07 · Relapsed or Metastatic Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07277322 · Dan Feng
2026-09-01 – 2030-12-31 · Metastatic Colorectal Cancer, Liver Metastases
What this study did
NCT07559929 · Hangzhou DAC Biotechnology Co., Ltd.
2026-08-19 – 2030-12-30 · Small Cell Lung Cancer
What this study did
NCT07245901 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-12-05 – 2030-12-05 · Solid Tumor
What this study did
NCT07630363 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-05-14 – 2030-04-01 · Advanced Renal Cell Carcinoma (RCC), PTC, Atorvastatin, Targeted Therapy Combined With Immunotherapy
What this study did
NCT06953323 · Wigen Biomedicine Technology (Shanghai) Co., Ltd.
2025-07-10 – 2029-12-30 · Advanced Solid Tumor
What this study did
NCT06682780 · LaNova Medicines Limited
2025-09-17 – 2029-12-01 · Advanced Solid Tumor
What this study did
NCT07392736 · Advenchen Laboratories, LLC
2021-10-26 – 2029-11-07 · Solid Tumor
What this study did
NCT07508761 · Nanjing Immunophage Biotech Co., Ltd
2026-06-16 – 2029-07-30 · Advanced Solid Tumor
What this study did
NCT06341400 · Zhujiang Hospital
2024-06-19 – 2029-05-01 · Bladder Cancer, Muscle-Invasive Bladder Carcinoma
What this study did
NCT06771622 · FBD Biologics Limited
2025-03-13 – 2029-01-01 · Solid Cancer
What this study did
NCT07281716 · Dan Feng
2025-12-01 – 2028-12-15 · Metastatic Microsatellite Stable Colorectal Carcinoma
What this study did
NCT06975293 · STORM Therapeutics LTD
2025-05-05 – 2028-06-29 · Solid Tumor, Sarcoma, Leiomyosarcoma, Dedifferentiated Liposarcoma
What this study did
NCT06612632 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-05-24 – 2028-06 · Cancer
What this study did
NCT06868199 · LaNova Medicines Limited
2025-05-06 – 2028-02-01 · Advanced Solid Tumours
What this study did
NCT05615974 · LaNova Medicines Limited
2023-01-11 – 2028-01-11 · Malignant Tumors
What this study did
NCT06079112 · Mabwell (Shanghai) Bioscience Co., Ltd.
2023-09-27 – 2027-12-31 · Advanced Urothelial Carcinoma
What this study did
NCT07727993 · Ting Liu
2026-08-01 – 2027-12-31 · Gastric or Gastroesophageal Junction Adenocarcinoma, Propranolol, SOX Chemotherapy, Toripalimab
What this study did
NCT06088004 · Suzhou Abogen Biosciences Co., Ltd.
2023-09-28 – 2027-12-30 · Solid Tumor, Adult
What this study did
NCT07099430 · Nanjing Leads Biolabs Co.,Ltd
2025-09-05 – 2027-12-30 · Advanced Melanoma
What this study did
NCT07040228 · Junjie Hang
2025-05-26 – 2027-05-30 · Pancreatic Cancer Metastatic
What this study did
NCT06370754 · Fudan University
2024-04-30 – 2027-04-30 · Pancreatic Cancer
What this study did
NCT06208410 · Risen (Suzhou) Pharma Tech Co., Ltd.
2024-01-11 – 2027-02-26 · Advanced Solid Tumors
What this study did
NCT04785196 · Ascentage Pharma Group Inc.
2021-05-26 – 2027-01 · Liposarcoma, Advanced Solid Tumor
What this study did
NCT05539118 · Xijing Hospital
2022-09-30 – 2026-12-31 · Melanoma
What this study did
NCT06462222 · Guangzhou Medical University
2024-06-30 – 2026-11 · Leptomeningeal Metastasis
What this study did
NCT05518045 · LaNova Medicines Limited
2022-08-26 – 2026-10-31 · Advanced Solid Tumor
What this study did
NCT06038396 · RemeGen Co., Ltd.
2023-08-03 – 2026-08-31 · Advanced Solid Tumor
What this study did
NCT05986227 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2023-08-01 – 2026-07-01 · Gastroesophageal Adenocarcinoma
What this study did
NCT06093438 · Tianjin Medical University Cancer Institute and Hospital
2023-11-01 – 2026-07-01 · Cervical Cancer, Induction Chemotherapy, Immunotherapy
What this study did
NCT03985891 · Xiangya Hospital of Central South University
2020-12-16 – 2026-06-01 · Colonic Neoplasms, Chemotherapy Effect
What this study did
NCT06139211 · Shanghai Junshi Bioscience Co., Ltd.
2023-12-06 – 2026-05-28 · Advanced Solid Tumor
What this study did
NCT05173142 · Hutchison Medipharma Limited
2022-01-22 – 2026-01-17 · Solid Tumor
What this study did
NCT05723432 · Shanghai Kanda Biotechnology Co., Ltd.
2023-03-22 – 2025-12-31 · Melanoma
What this study did
NCT04058470 · Huiqiang Huang
2020-04-24 – 2025-12-30 · Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma, EBV-Positive DLBCL, Nos, ALK-Positive Anaplastic Large Cell Lymphoma
What this study did
NCT06221774 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2024-02-01 – 2025-11-30 · Clear Cell Renal Carcinoma, Urothelial Carcinoma, Metastatic Castration-resistant Prostate Cancer
What this study did
NCT06117566 · Shanghai Jiatan Pharmatech Co., Ltd
2022-11-18 – 2025-11-09 · Solid Tumor
What this study did
NCT05664971 · Shanghai Junshi Bioscience Co., Ltd.
2023-02-09 – 2025-10-23 · Advanced Lung Cancer
What this study did
NCT04322006 · TJ Biopharma Co., Ltd.
2020-05-09 – 2025-04-30 · Advanced Solid Tumor
What this study did
NCT05024812 · The First Affiliated Hospital of Zhengzhou University
2022-06-01 – 2025-02 · Metastatic Gastric Cancer
What this study did
NCT04996771 · Sun Yat-sen University
2021-11-09 – 2024-12-31 · Small Cell Lung Carcinoma
What this study did
NCT04284488 · Ascentage Pharma Group Inc.
2020-04-10 – 2024-11-30 · Advanced Solid Tumor
What this study did
Phase 1 (74)
Nasopharyngeal Carcinoma
NCT05751486 · Shanghai Junshi Bioscience Co., Ltd.
2022-11-16 – 2024-10-31 · Advanced Nasopharyngeal Carcinoma
What this study did
NCT04073784 · Sun Yat-sen University
2019-06-08 – 2024-04-01 · Nasopharyngeal Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07683832 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2026-07-28 – 2031-04-17 · Non-Small Cell Lung Cancer NSCLC
What this study did
NCT07886229 · Second Xiangya Hospital of Central South University
2026-06-01 – 2029-12-31 · Resectable Non-Small-Cell Lung Cancer
What this study did
NCT04374877 · Coherus Oncology, Inc.
2020-04-22 – 2025-06-05 · Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
What this study did
NCT05021328 · Hubei Cancer Hospital
2021-10-01 – 2025-02-05 · NSCLC
What this study did
NCT06208033 · Fujian Cancer Hospital
2024-01-10 – 2024-12-30 · EGFR Positive Non-small Cell Lung Cancer
What this study did
NCT05757492 · Coherus Oncology, Inc.
2023-04-26 – 2024-07-31 · Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
What this study did
NCT04193098 · Tianjin Medical University Cancer Institute and Hospital
2019-06-01 – 2021-06-01 · Non-small Cell Lung Cancer, Second-line Treatment
What this study did
NCT03301688 · Shanghai Junshi Bioscience Co., Ltd.
2017-09-18 – 2019-12-15 · NSCLC
What this study did
Other / comorbidity
NCT07583953 · Suzhou Abogen Biosciences Co., Ltd.
2026-04-17 – 2031-04-17 · Solid Tumors
What this study did
NCT07898124 · Metaclipse Therapeutics Corporation
2026-10-01 – 2031-02-28 · Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN), HNSCC, Neoplasm Recurrence, Local, Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
NCT07680582 · Ruijin Hospital
2026-06-09 – 2031-02-09 · Solid Tumor
What this study did
NCT07853053 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2027-01-01 – 2029-12-31 · Bladder Cancer
What this study did
NCT06882876 · Xiangya Hospital of Central South University
2025-07-10 – 2029-07-30 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07562841 · West China Hospital
2026-04-28 – 2029-04-30 · Advanced Melanoma
What this study did
NCT06283134 · China Medical University, China
2026-03 – 2028-12-01 · Colorectal Cancer Metastatic
What this study did
NCT07550842 · Shanghai Best-Link Bioscience, LLC
2026-06-16 – 2028-08-18 · Small Cell Carcinoma of Lung
What this study did
NCT06389526 · Coherus Oncology, Inc.
2025-02-15 – 2028-05-30 · Advanced or Metastatic Solid Tumors
What this study did
NCT04387084 · University of Southern California
2020-08-12 – 2028-03-31 · Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
What this study did
NCT07625423 · West China Hospital
2026-03-27 – 2028-03-30 · Head & Neck Cancer, Nasopharyngeal Cancinoma (NPC)
What this study did
NCT06732258 · Sichuan University
2025-01-10 – 2028-02-29 · Extensive-stage Small-cell Lung Cancer
What this study did
NCT06832982 · Shanghai Pushi Medical Science Co. Ltd
2025-02-24 – 2028-02-19 · Advanced Solid Tumors
What this study did
NCT06657144 · Coherus Oncology, Inc.
2025-04-01 – 2028-01 · Metastatic Solid Tumor, Advanced Solid Tumor
What this study did
NCT07004244 · Sichuan University
2025-06-05 – 2027-12-31 · Malignant Tumors
What this study did
NCT05502393 · Shanghai Junshi Bioscience Co., Ltd.
2022-07-26 – 2027-12-31 · Advanced Solid Tumors
What this study did
NCT06577532 · Ruijin Hospital
2024-09-24 – 2027-08 · Pancreatic Neoplasms, Other Solid Tumors
What this study did
NCT07835035 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-07-06 – 2027-06-30 · Advanced Urothelial Carcinoma
What this study did
NCT06571422 · Shanghai Junshi Bioscience Co., Ltd.
2024-10-23 – 2027-04-30 · Advanced Malignant Solid Tumors
What this study did
NCT05579275 · Peking University Cancer Hospital & Institute
2023-02-06 – 2027-04-28 · Malignant Solid Tumors
What this study did
NCT04947241 · Fifth Affiliated Hospital, Sun Yat-Sen University
2020-12-15 – 2027-01-15 · Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
What this study did
NCT05635643 · Coherus Oncology, Inc.
2022-12-15 – 2027-01-01 · Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
What this study did
NCT05253105 · Shanghai Junshi Bioscience Co., Ltd.
2022-03-15 – 2027-01 · Previously Treated, Advanced, Malignancies
What this study did
NCT05650203 · Shanghai Junshi Bioscience Co., Ltd.
2023-03-31 – 2026-12-31 · Primary Condition: Advanced Tumors
What this study did
NCT05167071 · Harbour BioMed (Guangzhou) Co. Ltd.
2021-12-28 – 2026-06-30 · Solid Tumors, Neuroendocrine Tumors, CRC
What this study did
NCT04819516 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-12-07 – 2025-12 · Colorectal Cancer
What this study did
NCT06283303 · China Medical University, China
2024-04-02 – 2025-11-30 · Colorectal Cancer Metastatic
What this study did
NCT06078982 · Shanghai East Hospital
2023-06-06 – 2025-08 · Gastric Cancer, HER2-low-expressing Gastric Cancer
What this study did
NCT04197882 · Peking University Cancer Hospital & Institute
2019-05-27 – 2025-05-27 · Melanoma
What this study did
NCT05657418 · Shanghai Junshi Bioscience Co., Ltd.
2022-03-29 – 2025-01-04 · Advanced Pancreatic Cancer
What this study did
NCT04280341 · Peking University
2020-06-03 – 2024-12 · HER2-Positive Solid Tumors
What this study did
NCT04605185 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-01-08 – 2024-12 · Unresectable Hepatocellular Carcinoma
What this study did
NCT05798533 · BGI, China
2023-01-10 – 2024-09 · Solid Tumor
What this study did
NCT04640545 · Nanjing Leads Biolabs Co.,Ltd
2020-05-12 – 2024-08-19 · Advanced Melanoma
What this study did
NCT05262842 · Shanghai Junshi Bioscience Co., Ltd.
2022-03-29 – 2024-06-06 · Advanced Cancer
What this study did
NCT04926753 · Ruijin Hospital
2021-06-01 – 2024-06-01 · Locoregionally Advanced Laryngo-hypopharyngeal Squamous Cell Cancer
What this study did
NCT05149027 · Harbour BioMed (Guangzhou) Co. Ltd.
2021-12-20 – 2024-05-30 · Solid Tumors
What this study did
NCT04991506 · Elpiscience Biopharma, Ltd.
2021-10-15 – 2024-05-17 · Solid Tumor, Neoplasms, Malignant Tumor
What this study did
Phase 4 (3)
Other / comorbidity
NCT06457503 · Coherus Oncology, Inc.
2024-11-01 – 2027-12 · Nasopharyngeal Cancer Recurrent
What this study did
NCT05291910 · Chinese Academy of Medical Sciences
2022-03-12 – 2025-12-31 · Breast Cancer
What this study did
Early phase / not applicable (17)
Cholangiocarcinoma
NCT06313554 · Fudan University
2024-05-20 – 2027-05-20 · Intrahepatic Cholangiocarcinoma
What this study did
NCT05215665 · Tianjin Medical University Cancer Institute and Hospital
2022-01-15 – 2026-01-15 · Cholangiocarcinoma
What this study did
Nasopharyngeal Carcinoma
NCT06313450 · Sun Yat-sen University
2024-03-04 – 2028-02-01 · Nasopharyngeal Carcinoma, Radiotherapy; Complications, IMMUNOTHERAPY
What this study did
Non-Small Cell Lung Cancer
NCT06709274 · Guangdong Association of Clinical Trials
2024-11 – 2032-01 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07928362 · Ruijin Hospital
2026-10-28 – 2029-08-30 · Pancreatic Neoplasms, Neoplasm Metastasis
What this study did
NCT07500831 · Qilu Hospital of Shandong University
2026-04 – 2029-04 · Carcinoma, Renal Cell, Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma
What this study did
NCT06256224 · Ruijin Hospital
2024-02-02 – 2028-12-31 · Cervical Cancer, Chemoradiotherapy, Immunotherapy
What this study did
NCT05877573 · Nanfang Hospital, Southern Medical University
2023-07-01 – 2026-08-01 · Locally Advanced, High-Risk, Rectal Cancer, MSS
What this study did
NCT06371274 · First Affiliated Hospital of Zhejiang University
2024-10-10 – 2026-04-30 · Triple-negative Breast Cancer
What this study did
NCT04867330 · Fudan University
2021-02-01 – 2026-01 · Oropharyngeal Carcinoma, Immune Checkpoint Inhibitor, De-escalation
What this study did
NCT05162898 · Henan Cancer Hospital
2022-01 – 2025-12 · Recurrent Hepatocellular Cancer
What this study did
NCT06028672 · Peking Union Medical College Hospital
2023-09-12 – 2025-08 · Gestational Trophoblastic Neoplasia
What this study did
NCT05478473 · Peking University Cancer Hospital & Institute
2022-10-27 – 2024-08 · Melanoma
What this study did
NCT05056116 · The Affiliated Hospital of Xuzhou Medical University
2021-09-01 – 2024-06 · Biliary Tract Cancer
What this study did
NCT04443036 · China Medical University, China
2020-06-11 – 2023-12-30 · Gastric Carcinoma
What this study did
NCT04731909 · Third Military Medical University
2018-10-01 – 2023-06-30 · SCLC, Extensive Stage, Lung Cancer, Small Cell Lung Cancer
What this study did
NCT04944511 · Beijing Friendship Hospital
2021-07-01 – 2023-05 · PD-1 Antibody, Mixed Chimerism
What this study did
Used as active comparator (9)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (6)
Nasopharyngeal Carcinoma
Non-Small Cell Lung Cancer
NCT07672223 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-07-30 – 2031-11-30 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07823348 · Shanghai Junshi Bioscience Co., Ltd.
2026-10-08 – 2031-10-30 · Hepatocellular Carcinoma
What this study did
NCT07693959 · Zhiquan Hu
2026-07-01 – 2029-07-01 · MIBC
What this study did
NCT07446335 · The First Affiliated Hospital of Zhengzhou University
2026-04 – 2029-06 · Advanced Esophageal Squamous Cell Carcinoma
What this study did
NCT07111832 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-08-20 – 2028-12 · PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
What this study did
Phase 2/3 (1)
Phase 2 (1)
Other / comorbidity
NCT06642545 · RemeGen Co., Ltd.
2025-02-10 – 2027-10-01 · Breast Cancer
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT07281976 · Nanjing Leads Biolabs Co.,Ltd
2026-01-27 – 2027-12-31 · Triple Negative Breast Cancer
What this study did
Appears in other studies (14)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (3)
Nasopharyngeal Carcinoma
NCT07340515 · Man Hu
2025-12-15 – 2031-12-31 · Nasopharyngeal Carcinoma (NPC)
What this study did
Non-Small Cell Lung Cancer
NCT06437977 · Shanghai Chest Hospital
2024-09-12 – 2029-06 · Stage II-III Non-small Cell Lung Cancer
What this study did
NCT07251582 · Hunan Province Tumor Hospital
2026-08-12 – 2029-05-31 · Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT07756008 · Tianjin Medical University Second Hospital
2026-08-01 – 2031-06-20 · Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer, Bladder Cancer
What this study did
Phase 2 (6)
Other / comorbidity
NCT07922928 · Sun Yat-sen University
2026-11-10 – 2030-12-31 · Nonmetastatic Locally Advanced Non-Clear Cell Renal Cell Carcinoma
What this study did
NCT06039631 · Fudan University
2023-08-22 – 2029-09-01 · Larynx Cancer, Hypopharyngeal Cancer
What this study did
NCT07172412 · Tianjin Medical University Cancer Institute and Hospital
2025-11 – 2028-12 · Extensive Stage Lung Small Cell Cancer
What this study did
NCT06502080 · Shanghai Zhongshan Hospital
2024-07 – 2028-06-30 · Biliary Tract Cancer
What this study did
NCT06861712 · Sun Yat-sen University
2025-05-06 – 2026-12-31 · Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Stereotactic Body Radiation Therapy (SBRT)
What this study did
NCT03939975 · Sun Yat-sen University
2019-06-01 – 2019-07-31 · Carcinoma, Hepatocellular
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT03864211 · Xiangya Hospital of Central South University
2019-06-15 – 2023-05-30 · Hepatocellular Carcinoma Non-resectable
What this study did
Phase 1 (2)
Non-Small Cell Lung Cancer
NCT03732664 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2018-10-01 – 2023-03-23 · High-Risk Resectable NSCLC
What this study did
Other / comorbidity
NCT04731038 · Ruijin Hospital
2021-08-01 – 2024-07-01 · Advanced Cervical Cancer
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07067450 · Sichuan University
2025-07-20 – 2026-12-31 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Toripalimab: this drugPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04158440: Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met.
NCT03856411: Median PFS: 8.4 months (toripalimab plus chemotherapy) vs 5.6 months (placebo plus chemotherapy); HR 0.49 (95% CI 0.39-0.61), P<0.0001
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
AlmonertinibPhase 3Small moleculeEGFRPartial signal
NCT04500717: ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205).
AndamertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
BAT3306Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
CT-P51Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DostarlimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
MB12Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
RetifanlimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04205812: Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7)
SerplulimabPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
SintilimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03150875: Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022).
NCT03607539: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) (Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)): Sintilimab Combination 8.9 Months (95% CI 7.1 to 11.3) vs Placebo Combination 5 Months (95% CI 4.8 to 6.2)
TislelizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
BudigalimabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
SasanlimabPhase 2/3Monoclonal antibodyPD-1Partial signalFeatured results are dose-finding only in this race
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Pemigatinib (Pemazyre)Phase 2Small moleculeFGFR1/2/3Weak signal
NCT05253807: Objective Response Rate (ORR) in Cohort A (up to 267 days): Cohort A: Squamous NSCLC 33.3% (95% CI 0.84 to 90.57)
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
TagitanlimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
IOV-4001Phase 1/2Cell therapyPD-1not yet gradedNo reviewed efficacy summary in this indication
OSE-279Phase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 1/2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 90 furthest-along competitors are listed; 523 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(209 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Toripalimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (24)
November 2026 (1)
Phase 1/2Leptomeningeal MetastasisActive not recruiting
Est. primary completion 2026-11 · NCT06462222 · CT.gov ↗
What to watch
December 2026 (23)
Phase 1Pancreatic Neoplasms, Other Solid TumorsRecruiting
Est. primary completion 2026-12 · NCT06577532 · CT.gov ↗
What to watch
Phase 2Microsatellite Stable Metastatic Colorectal CancerRecruiting
Est. primary completion 2026-12 · NCT06525428 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerNot yet recruiting
Est. primary completion 2026-12 · NCT06654947 · CT.gov ↗
What to watch
Phase 2Cervical CancersActive not recruiting
Est. primary completion 2026-12 · NCT06416696 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06323239 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12 · NCT06914440 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2026-12 · NCT05340491 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-01 · NCT06426511 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Solid TumorsActive not recruiting
Est. primary completion 2026-12-15 · NCT06571422 · CT.gov ↗
What to watch
Phase 1/2Solid Tumor, AdultRecruiting
Est. primary completion 2026-12-30 · NCT06088004 · CT.gov ↗
What to watch
Phase 2Non-clear Renal Cell CarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT05768464 · CT.gov ↗
What to watch
Phase 2Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma, Solitary KidneyRecruiting
Est. primary completion 2026-12-30 · NCT06354231 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT04772287 · CT.gov ↗
What to watch
Phase 1/2Advanced Urothelial CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06079112 · CT.gov ↗
What to watch
Phase 2Locally Advanced Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06187597 · CT.gov ↗
What to watch
Phase 2CholangiocarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT06717464 · CT.gov ↗
What to watch
Phase 2Stomach NeoplasmsRecruiting
Est. primary completion 2026-12-31 · NCT05033392 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT05798845 · CT.gov ↗
What to watch
Phase 2Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, RadiotherapyActive not recruiting
Est. primary completion 2026-12-31 · NCT05975307 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2026-12-31 · NCT04918186 · CT.gov ↗
What to watch
Phase 2/3Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT03859128 · CT.gov ↗
What to watch
Phase 3Urothelial Carcinoma, HER2-expressingRecruiting
Est. primary completion 2026-12-31 · NCT05302284 · CT.gov ↗
What to watch
Phase 3Advanced Hepatocellular Carcinoma (HCC)Active not recruiting
Est. primary completion 2026-12-31 · NCT04523493 · CT.gov ↗
What to watch
2027 (82)
January 2027 (8)
Phase 2Paget Disease, Extramammary, Scrotum DiseaseRecruiting
Est. primary completion 2027-01 · NCT06791070 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-01 · NCT07493980 · CT.gov ↗
What to watch
Phase 1Hepatocellular Carcinoma (HCC)Enrolling by invitation
Est. primary completion 2027-01-01 · NCT06882876 · CT.gov ↗
What to watch
Phase 2Advanced Urothelial Carcinoma, Probiotics, ImmunotherapyRecruiting
Est. primary completion 2027-01-01 · NCT06904573 · CT.gov ↗
What to watch
Phase 1/2Malignant TumorsRecruiting
Est. primary completion 2027-01-11 · NCT05615974 · CT.gov ↗
What to watch
Phase 2Soft Tissue SarcomaRecruiting
Est. primary completion 2027-01-30 · NCT04589741 · CT.gov ↗
What to watch
Phase 2Limited Stage Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-31 · NCT06256237 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-31 · NCT06269211 · CT.gov ↗
What to watch
February 2027 (5)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-02-26 · NCT06208410 · CT.gov ↗
What to watch
Phase 1Advanced Urothelial CarcinomaRecruiting
Est. primary completion 2027-02-28 · NCT07835035 · CT.gov ↗
What to watch
Phase 2Radiation Therapy, Targeted Therapy, Immunotherapy, Renal Cancer MetastaticRecruiting
Est. primary completion 2027-02-28 · NCT06889649 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-02-28 · NCT07438600 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-02-28 · NCT06623136 · CT.gov ↗
What to watch
March 2027 (4)
Phase 3HR+/HER2- Breast CancerRecruiting
Est. primary completion 2027-03-23 · NCT06977893 · CT.gov ↗
What to watch
Phase 1/2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2027-03-28 · NCT07320963 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
Phase 3Gastric or Esophagogastric Junction AdenocarcinomaActive not recruiting
Est. primary completion 2027-03-31 · NCT05180734 · CT.gov ↗
What to watch
April 2027 (2)
Phase 2Muscle-Invasive Bladder Cancer (MIBC)Recruiting
Est. primary completion 2027-04 · NCT07647289 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant TherapyRecruiting
Est. primary completion 2027-04-01 · NCT03926338 · CT.gov ↗
What to watch
May 2027 (5)
Phase 2Biliary Tract Cancer (BTC)Not yet recruiting
Est. primary completion 2027-05-01 · NCT06919848 · CT.gov ↗
What to watch
Phase 3Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-05-12 · NCT04848753 · CT.gov ↗
What to watch
Phase 1/2Pancreatic Cancer MetastaticRecruiting
Est. primary completion 2027-05-30 · NCT07040228 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint InhibitorsNot yet recruiting
Est. primary completion 2027-05-31 · NCT07159217 · CT.gov ↗
What to watch
Phase 3CholangiocarcinomaRecruiting
Est. primary completion 2027-05-31 · NCT05342194 · CT.gov ↗
What to watch
June 2027 (6)
Phase 2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-06 · NCT06851247 · CT.gov ↗
What to watch
Phase 2Triple Negative Breast NeoplasmsNot yet recruiting
Est. primary completion 2027-06 · NCT07040644 · CT.gov ↗
What to watch
Phase 1/2Gastric or Gastroesophageal Junction Adenocarcinoma, Propranolol, SOX Chemotherapy, ToripalimabNot yet recruiting
Est. primary completion 2027-06-30 · NCT07727993 · CT.gov ↗
What to watch
Phase 2Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT06878625 · CT.gov ↗
What to watch
Phase 2Advanced Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06-30 · NCT07484724 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-06-30 · NCT06235203 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Advanced Colorectal CancerRecruiting
Est. primary completion 2027-07-31 · NCT07106034 · CT.gov ↗
What to watch
Phase 3Limited-stage Small Cell Lung Cancer (LS-SCLC)Recruiting
Est. primary completion 2027-07-31 · NCT06095583 · CT.gov ↗
What to watch
August 2027 (6)
Phase 2Advanced Breast CancerRecruiting
Est. primary completion 2027-08 · NCT07540533 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumoursRecruiting
Est. primary completion 2027-08-01 · NCT06868199 · CT.gov ↗
What to watch
Phase 2Locally Advanced Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT06843889 · CT.gov ↗
What to watch
Phase 2Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07088211 · CT.gov ↗
What to watch
Phase 2Urothelial Carcinoma of the Renal Pelvis and Ureter, Neoadjuvant TherapyNot yet recruiting
Est. primary completion 2027-08-01 · NCT07720921 · CT.gov ↗
What to watch
Phase 2UrologyNot yet recruiting
Est. primary completion 2027-08-30 · NCT07151560 · CT.gov ↗
What to watch
September 2027 (5)
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2027-09 · NCT05484375 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2027-09 · NCT06679985 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaRecruiting
Est. primary completion 2027-09 · NCT06592326 · CT.gov ↗
What to watch
Phase 1Bladder CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07783815 · CT.gov ↗
What to watch
Phase 2Head and Neck CancerRecruiting
Est. primary completion 2027-09-01 · NCT06208826 · CT.gov ↗
What to watch
October 2027 (4)
Phase 2Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder, Non-Muscle-Invasive Bladder CancerNot yet recruiting
Est. primary completion 2027-10 · NCT07189793 · CT.gov ↗
What to watch
Phase 2Urinary Bladder CancerRecruiting
Est. primary completion 2027-10-03 · NCT04861584 · CT.gov ↗
What to watch
Phase 1/2Advanced MelanomaRecruiting
Est. primary completion 2027-10-30 · NCT07099430 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-10-31 · NCT06378177 · CT.gov ↗
What to watch
November 2027 (4)
Phase 2Gastric Cancer, MetastaticNot yet recruiting
Est. primary completion 2027-11-30 · NCT06283121 · CT.gov ↗
What to watch
Phase 2TNBC - Triple-Negative Breast CancerNot yet recruiting
Est. primary completion 2027-11-30 · NCT07101614 · CT.gov ↗
What to watch
Phase 2Advanced Lung CancerRecruiting
Est. primary completion 2027-11-30 · NCT07309276 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Solid TumorsRecruiting
Est. primary completion 2027-11-30 · NCT07480733 · CT.gov ↗
What to watch
December 2027 (31)
Phase 2Carcinoma, Upper Tract Urothelial Carcinoma, UTUCRecruiting
Est. primary completion 2027-12 · NCT05917158 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Recruiting
Est. primary completion 2027-12 · NCT07481058 · CT.gov ↗
What to watch
Phase 4Nasopharyngeal Cancer RecurrentRecruiting
Est. primary completion 2027-12 · NCT06457503 · CT.gov ↗
What to watch
Phase 1Colorectal Cancer MetastaticNot yet recruiting
Est. primary completion 2027-12-01 · NCT06283134 · CT.gov ↗
What to watch
Phase 2Bladder CancerRecruiting
Est. primary completion 2027-12-08 · NCT07307456 · CT.gov ↗
What to watch
Phase 2Muscle-invasive Bladder Urothelial CarcinomaNot yet recruiting
Est. primary completion 2027-12-10 · NCT07279597 · CT.gov ↗
What to watch
Phase 3Esophageal Squamous Cell Carcinoma (ESCC)Recruiting
Est. primary completion 2027-12-15 · NCT07246330 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-18 · NCT07286942 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaActive not recruiting
Est. primary completion 2027-12-20 · NCT05869227 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruiting
Est. primary completion 2027-12-25 · NCT07272291 · CT.gov ↗
What to watch
Phase 3Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruiting
Est. primary completion 2027-12-28 · NCT06952621 · CT.gov ↗
What to watch
Phase 1/2Solid Tumor, Sarcoma, Leiomyosarcoma, Dedifferentiated LiposarcomaRecruiting
Est. primary completion 2027-12-29 · NCT06975293 · CT.gov ↗
What to watch
Phase 2Muscle Invasive Bladder Cancer (MIBC)Not yet recruiting
Est. primary completion 2027-12-30 · NCT07201675 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Active not recruiting
Est. primary completion 2027-12-30 · NCT07380633 · CT.gov ↗
What to watch
Phase 2Oligometastatic Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12-30 · NCT07744932 · CT.gov ↗
What to watch
Phase 2Metastatic Non-Clear Cell Renal Cell Carcinoma, Metastatic Renal Medullary CarcinomasNot yet recruiting
Est. primary completion 2027-12-30 · NCT07816770 · CT.gov ↗
What to watch
Phase 1Malignant TumorsRecruiting
Est. primary completion 2027-12-31 · NCT07004244 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsActive not recruiting
Est. primary completion 2027-12-31 · NCT05502393 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07314723 · CT.gov ↗
What to watch
Phase 2Cervical Cancer, Recurrent, MetastaticNot yet recruiting
Est. primary completion 2027-12-31 · NCT07363330 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07555860 · CT.gov ↗
What to watch
Phase 2Clear Cell RCCRecruiting
Est. primary completion 2027-12-31 · NCT07571551 · CT.gov ↗
What to watch
Phase 2ER+/HER2- Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT06964906 · CT.gov ↗
What to watch
Phase 2Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07776717 · CT.gov ↗
What to watch
Phase 2Advanced Biliary Tract CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07897565 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck CancerRecruiting
Est. primary completion 2027-12-31 · NCT07214987 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07876557 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07653451 · CT.gov ↗
What to watch
Phase 3Renal Cell Carcinoma, NeoadjuvantRecruiting
Est. primary completion 2027-12-31 · NCT05738694 · CT.gov ↗
What to watch
Early phase / not applicablePancreatic Neoplasms, Neoplasm MetastasisNot yet recruiting
Est. primary completion 2027-12-31 · NCT07928362 · CT.gov ↗
What to watch
2028 (64)
January 2028 (10)
Phase 1Metastatic Solid Tumor, Advanced Solid TumorRecruiting
Est. primary completion 2028-01 · NCT06657144 · CT.gov ↗
What to watch
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT07358689 · CT.gov ↗
What to watch
Phase 2Rectal Adenocarcinoma, High-risk Locally Advanced, Short-course Radiotherapy (SCRT), Immunotherapy, FOLFOXRecruiting
Est. primary completion 2028-01-01 · NCT07669220 · CT.gov ↗
What to watch
Phase 2TNBC, Triple Negative Breast CancerRecruiting
Est. primary completion 2028-01-04 · NCT07457359 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Advanced CancerRecruiting
Est. primary completion 2028-01-15 · NCT03810339 · CT.gov ↗
What to watch
Phase 2Advanced Solid TumorNot yet recruiting
Est. primary completion 2028-01-26 · NCT06873854 · CT.gov ↗
What to watch
Phase 2TNBC - Triple-Negative Breast Cancer, PD-L1 PositiveNot yet recruiting
Est. primary completion 2028-01-30 · NCT07244874 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Cancinoma (NPC), Nasopharangeal CancerRecruiting
Est. primary completion 2028-01-30 · NCT07325539 · CT.gov ↗
What to watch
Phase 2Pancreatic Cancer ResectableNot yet recruiting
Est. primary completion 2028-01-31 · NCT07469956 · CT.gov ↗
What to watch
February 2028 (5)
Phase 1/2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2028-02 · NCT07258979 · CT.gov ↗
What to watch
Phase 2HR Positive/HER2 Low Breast CancerRecruiting
Est. primary completion 2028-02-01 · NCT07383818 · CT.gov ↗
What to watch
Phase 2Sinonasal Cancer, Paranasal Sinus Neoplasms, Squamous Cell Carcinoma, Sinonasal Undifferentiated Carcinoma …Recruiting
Est. primary completion 2028-02-01 · NCT06940180 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2028-02-19 · NCT06832982 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-02-21 · NCT07410234 · CT.gov ↗
What to watch
March 2028 (4)
Phase 1/2Advanced Renal Cell Carcinoma (RCC), PTC, Atorvastatin, Targeted Therapy Combined With ImmunotherapyNot yet recruiting
Est. primary completion 2028-03-01 · NCT07630363 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2028-03-01 · NCT07388836 · CT.gov ↗
What to watch
Phase 2Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates, Immunotherapy, Chemotherapy, Systemic TherapyNot yet recruiting
Est. primary completion 2028-03-01 · NCT07879469 · CT.gov ↗
What to watch
Phase 1Head & Neck Cancer, Nasopharyngeal Cancinoma (NPC)Recruiting
Est. primary completion 2028-03-30 · NCT07625423 · CT.gov ↗
What to watch
April 2028 (4)
Early phase / not applicableCarcinoma, Renal Cell, Metastatic Renal Cell Carcinoma, Advanced Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2028-04 · NCT07500831 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer, Microsatellite Instability High, Mismatch Repair DeficiencyRecruiting
Est. primary completion 2028-04-01 · NCT06903858 · CT.gov ↗
What to watch
Phase 1Small Cell Carcinoma of LungNot yet recruiting
Est. primary completion 2028-04-28 · NCT07550842 · CT.gov ↗
What to watch
Phase 1Advanced MelanomaRecruiting
Est. primary completion 2028-04-30 · NCT07562841 · CT.gov ↗
What to watch
May 2028 (4)
Phase 1/2Bladder Cancer, Muscle-Invasive Bladder CarcinomaRecruiting
Est. primary completion 2028-05-01 · NCT06341400 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)Not yet recruiting
Est. primary completion 2028-05-29 · NCT07796126 · CT.gov ↗

Company guidance: data expected 2H 2026 (Coherus BioSciences, Inc., 5 Aug 2026). “● The Phase 1b dose-optimization studies evaluating tagmokitug in combination with toripalimab in second-line head and neck squamous cell carcinoma (HNSCC) and upper gastrointestinal adenocarcinomas remain ongoing, with initial data readouts expected in 2H 2026.” Source ↗

What to watch
Phase 1Advanced or Metastatic Solid TumorsNot yet recruiting
Est. primary completion 2028-05-30 · NCT06389526 · CT.gov ↗
What to watch
Phase 3Esophageal Cancer, ChemoradiotherapyRecruiting
Est. primary completion 2028-05-31 · NCT07177794 · CT.gov ↗
What to watch
June 2028 (6)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-01 · NCT07559929 · CT.gov ↗
What to watch
Phase 1Solid TumorRecruiting
Est. primary completion 2028-06-30 · NCT07680582 · CT.gov ↗
What to watch
Phase 2CholangiocarcinomaNot yet recruiting
Est. primary completion 2028-06-30 · NCT07685535 · CT.gov ↗
What to watch
Phase 2Bladder Urothelial Carcinoma, Bladder CancerRecruiting
Est. primary completion 2028-06-30 · NCT07717242 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT06228079 · CT.gov ↗
What to watch
Phase 3Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruiting
Est. primary completion 2028-06-30 · NCT07445295 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Colorectal Cancer (CRC)Recruiting
Est. primary completion 2028-07-01 · NCT07896681 · CT.gov ↗
What to watch
Phase 4Biliary Tract Cancer (BTC)Recruiting
Est. primary completion 2028-07-01 · NCT07619235 · CT.gov ↗
What to watch
August 2028 (4)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-08-05 · NCT07855965 · CT.gov ↗
What to watch
Phase 3Locally Advanced or Metastatic GC and GCJ AdenocarcinomaRecruiting
Est. primary completion 2028-08-17 · NCT07362186 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2028-08-20 · NCT06561763 · CT.gov ↗
What to watch
Phase 2Oral Squamous Cell Carcinoma (OSCC)Not yet recruiting
Est. primary completion 2028-08-31 · NCT07778368 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-10 · NCT07906587 · CT.gov ↗
What to watch
Phase 2Non Muscle Invasive Bladder CancerNot yet recruiting
Est. primary completion 2028-10-01 · NCT07808216 · CT.gov ↗
What to watch
November 2028 (3)
Phase 3Nasopharyngeal CarcinomaActive not recruiting
Est. primary completion 2028-11-26 · NCT06712888 · CT.gov ↗
What to watch
Phase 2Toripalimab, Surufatinib, Chemoradiotherapy, Limited-stage Small Cell Lung Cancer (LS-SCLC)Recruiting
Est. primary completion 2028-11-29 · NCT06719700 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-11-30 · NCT06706219 · CT.gov ↗
What to watch
December 2028 (20)
Phase 2Upper Tract Urothelial CarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT07412171 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT07823270 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-01 · NCT07819578 · CT.gov ↗
What to watch
Phase 1/2Solid TumorNot yet recruiting
Est. primary completion 2028-12-05 · NCT07245901 · CT.gov ↗
What to watch
Phase 1/2Metastatic Microsatellite Stable Colorectal CarcinomaRecruiting
Est. primary completion 2028-12-15 · NCT07281716 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2028-12-25 · NCT06682780 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2028-12-30 · NCT07508761 · CT.gov ↗
What to watch
Phase 2Melanoma of Skin, Acral Melanoma, Stage II MelanomaRecruiting
Est. primary completion 2028-12-30 · NCT06965231 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-30 · NCT07039656 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07683832 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-31 · NCT07886229 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal Cancer, Liver MetastasesRecruiting
Est. primary completion 2028-12-31 · NCT07277322 · CT.gov ↗
What to watch
Phase 2Recurrent Rectal CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT06751394 · CT.gov ↗
What to watch
Phase 2TNBC - Triple-Negative Breast CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07256964 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaEnrolling by invitation
Est. primary completion 2028-12-31 · NCT05441475 · CT.gov ↗
What to watch
Phase 2Dermatofibrosarcoma Protuberans (DFSP)Not yet recruiting
Est. primary completion 2028-12-31 · NCT07646080 · CT.gov ↗
What to watch
Phase 2Advanced RCCRecruiting
Est. primary completion 2028-12-31 · NCT07611825 · CT.gov ↗
What to watch
Phase 2/3Rectal CancerRecruiting
Est. primary completion 2028-12-31 · NCT07935759 · CT.gov ↗
What to watch
Phase 3NK/T Cell Lymphoma NosRecruiting
Est. primary completion 2028-12-31 · NCT04365036 · CT.gov ↗
What to watch
Early phase / not applicableCervical Cancer, Chemoradiotherapy, ImmunotherapyRecruiting
Est. primary completion 2028-12-31 · NCT06256224 · CT.gov ↗
What to watch
2029 (26)
January 2029 (7)
Phase 2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2029-01 · NCT06592599 · CT.gov ↗
What to watch
Phase 2Undifferentiated Pleomorphic Sarcoma (UPS)Not yet recruiting
Est. primary completion 2029-01 · NCT07817095 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-01 · NCT06709274 · CT.gov ↗
What to watch
Phase 2Penile Squamous Cell Carcinoma (PSCC), Advanced Penile Cancer, Metastatic Penile Cancer, Locally Advanced Penile CancerNot yet recruiting
Est. primary completion 2029-01-01 · NCT07907861 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-01-30 · NCT07677475 · CT.gov ↗
What to watch
Phase 1Solid TumorsNot yet recruiting
Est. primary completion 2029-01-31 · NCT07583953 · CT.gov ↗
What to watch
Phase 3Gastric AdenocarcinomaRecruiting
Est. primary completion 2029-01-31 · NCT07584135 · CT.gov ↗
What to watch
March 2029 (2)
Phase 2Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage IIINot yet recruiting
Est. primary completion 2029-03-01 · NCT06903871 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2029-03-12 · NCT07362979 · CT.gov ↗
What to watch
April 2029 (2)
Phase 2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2029-04-20 · NCT06912711 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma …Recruiting
Est. primary completion 2029-04-30 · NCT07423078 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-05 · NCT07608159 · CT.gov ↗
What to watch
June 2029 (4)
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2029-06-01 · NCT06987123 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2029-06-30 · NCT06953323 · CT.gov ↗
What to watch
Phase 2Renal Cell Carcinoma (RCC), AdjuvantActive not recruiting
Est. primary completion 2029-06-30 · NCT07047001 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2029-06-30 · NCT07378306 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8Recruiting
Est. primary completion 2029-07-31 · NCT07140679 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2029-08-14 · NCT07110558 · CT.gov ↗
What to watch
September 2029 (3)
Phase 2Triple Negative Breast Cancer (TNBC)Recruiting
Est. primary completion 2029-09 · NCT06636981 · CT.gov ↗
What to watch
Phase 3Squamous Cell Carcinoma of Head and NeckNot yet recruiting
Est. primary completion 2029-09-30 · NCT06647563 · CT.gov ↗
What to watch
Phase 3Cervical Cancer MetastaticNot yet recruiting
Est. primary completion 2029-09-30 · NCT07392060 · CT.gov ↗
What to watch
October 2029 (1)
Phase 3Esophageal CancerNot yet recruiting
Est. primary completion 2029-10-01 · NCT07332221 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1/2Solid TumorRecruiting
Est. primary completion 2029-11-07 · NCT07392736 · CT.gov ↗
What to watch
December 2029 (3)
Phase 1Bladder CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07853053 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2029-12-31 · NCT07136519 · CT.gov ↗
What to watch
Phase 2/3Rectal CancerRecruiting
Est. primary completion 2029-12-31 · NCT07505472 · CT.gov ↗
What to watch
2030 (8)
January 2030 (1)
Phase 2SCLC, Extensive Stage, Bayesian, Metronomic ChemotherapyNot yet recruiting
Est. primary completion 2030-01-01 · NCT07698054 · CT.gov ↗
What to watch
February 2030 (2)
Phase 2Oropharyngeal CancerRecruiting
Est. primary completion 2030-02 · NCT07290621 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2030-02-20 · NCT06277050 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2/3Urinary Bladder NeoplasmsNot yet recruiting
Est. primary completion 2030-06-30 · NCT07608224 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Postoperative Incidental Small Cell Lung Cancer, Toripalimab Adjuvant Therapy EvaluationNot yet recruiting
Est. primary completion 2030-07 · NCT07097948 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharyngeal Cancer, Laryngeal Cancer …Recruiting
Est. primary completion 2030-10-01 · NCT07209189 · CT.gov ↗
What to watch
December 2030 (2)
Phase 1Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN), HNSCC, Neoplasm Recurrence, Local …Recruiting
Est. primary completion 2030-12-31 · NCT07898124 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2030-12-31 · NCT07836049 · CT.gov ↗
What to watch
2031 (3)
March 2031 (1)
Phase 2Muscle Invasive Bladder Cancer (MIBC)Not yet recruiting
Est. primary completion 2031-03-31 · NCT07474064 · CT.gov ↗
What to watch
August 2031 (1)
Phase 2Malignant Neoplasms of Digestive OrgansRecruiting
Est. primary completion 2031-08-06 · NCT05934331 · CT.gov ↗
What to watch
September 2031 (1)
Phase 3Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2031-09 · NCT07154069 · CT.gov ↗
What to watch
2032 (2)
March 2032 (1)
Phase 3Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2032-03-15 · NCT07629817 · CT.gov ↗
What to watch
December 2032 (1)
Phase 3Nasopharyngeal CarcinomaNot yet recruiting
Est. primary completion 2032-12-31 · NCT07540390 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

July 2026Filing acceptedNMPA accepts sNDA for perioperative toripalimab plus chemotherapy in stage II-III NSCLC
CN, NMPA · Source ↗